Nofiate

Indications

Nofiate is used to treat hyperlipidemias of type lla, llb, III, IV, and V in people who haven't reacted well to diet and other treatments.

 

Pharmacology

Fibric acid derivative fenofibrate. After oral intake, fenofibrate is quickly hydrolyzed to its pharmacologically active form, fenofibric acid. Total cholesterol, LDL cholesterol, Apo-lipoprotein B, total triglycerides, and VLDL cholesterol are all reduced by fenofibric acid. Furthermore, Fenofibrate therapy causes an increase in HDL and apo-proteins apoAI apoAII. Fenofibrate also lowers serum uric acid levels in hyperuricemic and non-hyperuricemic people by increasing uric acid excretion through the urine. In comparison to the non-micronised formulation, the micronised version of Nofiate (Fenofibrate) exhibits better absorption.

 

Dosage & Administration

• For the treatment of adult patients with hypercholesterolemia or mixed hyperlipidemia, the initial dose of Fenofibrate is 200 mg per day.
• For adult patients with hypertriglyceridemia, the initial dose is 67 to 200 mg per day.
• Dose should be individualized according to patient response. Fenofibrate should be given with meal there by, optimizing the bioavailability of the medication. Or, as directed by the registered physician.

 

Interaction

Warfarin's anticoagulant effects have been found to be potentiated by fenofibrate. It may increase glucose tolerance and have an additive effect when used with an anti-diabetic medication. Cyclosporine nephrotoxicity may be increased by fenofibrate. The use of Fenofibrate with HMG-CoA reductase inhibitors should be avoided due to a potential increase in the risk of rhabdomyolysis. Low-dose statins combined with Fenofibrate, on the other hand, appear to be well tolerated.

 

Contraindications

Hypersensitivity to Fenofibrate, severe renal or hepatic impairment, existing gall bladder disease, breast-feeding moms, and photosensitivity to ketoprofen are all contraindications to using Fenofibrate.

 

Side Effects

Myotoxicity (nausea, anorexia, stomach discomfort), pruritus, urticaria, impotence, as well as headache, dizziness, vertigo, tiredness, and hair loss.

 

Pregnancy & Lactation

Pregnant women should avoid using fenofibrate.

 

Precautions & Warnings

Patients with renal disease should be given extra attention since gradual increases in serum creatinine concentration or failure to follow dose requirements might lead to myotoxicity; stop if myotoxicity is suspected or if creatinine kinase concentration rises considerably. For the first year, liver function tests are advised every three months.

 

Therapeutic Class

Fibrates

 

Storage Conditions

Do not store at temperatures above 30°C. Keep out of the reach of youngsters and away from light.

 

Pharmaceutical Name

Incepta Pharmaceuticals Ltd

 

Generic

Fenofibrate

 

Related Products

• Fenocap
• Lipidof 200